Method for quantifying LBP in body fluids

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007100, C436S063000, C436S536000

Reexamination Certificate

active

07081334

ABSTRACT:
The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.

REFERENCES:
patent: 5245013 (1993-09-01), Ulevitch
patent: 5310879 (1994-05-01), Ulevitch
patent: 5484705 (1996-01-01), White
patent: WO 91/01639 (1991-02-01), None
patent: WO 93/06228 (1993-04-01), None
patent: WO 94/21280 (1994-09-01), None
patent: WO 94/25476 (1994-11-01), None
patent: WO 95/00641 (1995-01-01), None
patent: WO 95/02414 (1995-01-01), None
The abstract of Gardener et al (Journal of Reproductive Medicine, 1977, vol. 19, pp. 64-66).
The abstract of Grobler et al (Gut, Oct. 1993, vol. 34, pp. 1384-1388).
The abstract of Gelman et al (Radiology, 1977, vol. 122, pp. 17-23).
The abstract of Cohen et al (QJM, 1982, vol. 51, pp. 1-15).
The abstract of Allwright et al (Clinical Nuclear Medicine, 1988, vol. 13, pp. 506-508).
The abstract of Hunt (Journal of Immunology, 1989).
The abstract of Martin (Immunology, 1991, vol. 73, pp. 123-125).
Dofferhoff et al., “Tumor necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature”,Netherlands J. Med., 39:45-62 (1991).
Elsbach et al., “Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a Closely Associated Phospholipase A2from Rabbit Polymorphonuclear Leukocytes”,J. Biol. Chem., 254(21):11000-11009 (Nov. 10, 1979).
Erwin and Munford, “Plasma Lipopolysaccharide-Deacylating Activity (Acyloxyacyl Hydrolase) Increases After Lipopolysaccharide Administration to Rabbits”,Lab. Invest., 65(2):138-144 (1991).
Gallay et al., “Purification and Characterization of Murine Lipopolysaccharide-Binding Protein”,Infect. Immun. 61(2):378-383 (Feb. 1993).
Gazzano-Santoro et al., “High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide”,Infect. Immun. 60(11):4754-4761 (Nov. 1992).
Leturcq et al, “Generation of Monoclonal Antibodies to Human LBP and Their Use in the Detection of LBP Protein in Serum”,J. Cell. Biochem., 16C:161 (1992).
Marra et al., “The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin”,J. Immun., 148(2):532-537 (Jan. 15, 1992).
Pereira et al, “Quantitation of a cationic antimicrobial granule protein of human polymorphonuclear leukocytes by ELISA”,J. Immunol. Methods, 117:115-120 (1989).
Pesce et al., “Cationic antigens Problems associated with measurement by ELISA”,J. Immunol. Methods, 87:21-27 (1986).
Schindler et al., “Plasma levels of bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) during hemodialysis”,Clin. Nephrology, 40(6):346-351 (1993).
Schumann et al., “Structure and Function of Lipopolysaccharide Binding Protein”,Science, 249:1429-1433 (Sep. 21, 1990).
Spitznzgel, “Antibiotic Proteins of Human Neutrophilia”,J. Clin. Invest., 86:1381-1386 (1990).
Taber et al., Taber's Cyclopedic Medical Dictionary, pp. 545 (F.A. Davis Co., Philadelphia) (1985).
Ulevitch, Presentation at the merican Society of Microbiology General Meeting in Atlanta, Georgia (May 16-21, 1993).
von der Mohien et al., Bactericidal/Permeability-Increasing Protein Levels Predict Survival in Patients with Gram-Negative Sepsis, Abstract presented at 13th International Symposium on Intensive Care and Emergency Medicine, (Brussels, Belgium) (Mar. 1993).
Weiss and Olsson, “Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils”,Blood, 69(2):652-659 (Feb. 1987).
Weiss et al., “Human Bactericidal/Permeability-Increasing Protein and a Recombinant NH2- Terminal Fragment Cause Killing of Serum-resistant Gram-negative Bacteria in Whole Blood and Inhibit Tumor Necrosis Factor Release Induced by the Bacteria”,J. Clin. Invest. 90:1122-1130 (Sep. 1992).
Weiss et al., “Purification and Characterization of a Potent Bactericidal and Membrane Active Protein from the Granules of Human Polymorphonuclear Leukocytes”J. Biol. Chem., 253(8):2664-2672 (Apr. 25, 1978).
White et al., “Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA”,J. Immunol. Methods, 167:227-235 (1994).
Wright et al., “CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein”,Science, 249:1431-1433 (Sep. 21, 1990).
Ulevitch, Presentation at the American Society of Microbiology General Meeting in Atlanta, Georgia (May 16-21, 1993) (Session 13 Abstract 564).
Tobias et al., “Lipopolysaccharide Binding Protein”J. Cell. Biochem., 16 C:151 (Abstract (CB006) (1992).
Ballou et al., “Laboratory Evaluation of Inflammation,”Textbook of Rheumatology, vol. 1, Ch. 40, pp. 671-679 (1993).
Baumann et al., “The acute phase response,”Immunology Today, vol. 15, 1/31 2, pp. 74-80 1994).
Grube et al., “Lipopolysaccharide Binding Protein Expression in Primary Human Hepatocytes and HepG2 Hepatoma Cells*,”J. Biol. Chem., vol. 269, No. 11, pp. 8477-8482 (1994).
Raynes, “Carbohydrate Binding Proteins and Immune Responses,” Biochemical Immunology Group/Glycobiology Group Joint Colloquium Organized by G.B. Wisdom and M.I. Halliday (The Queen's University, Belfast) and Edited by G.B. Wisdom. 648th Meeting held at the Queen's University, Belfast, Sep. 14-17, 1993,Biochemical Society Transactions, vol. 22, pp. 69-74 (1994).
Meszaros et al., “Immunoreactivity and Bioactivity of Lipopolysaccharide-Binding Protein in Normal and Heat-Inactivated Sera,”Infection and Immunity, vol. 63, No. 1, pp. 363-366 (1995).
Pugin et al., “Soluble CD14 and Lipopolysaccharide Binding Protein Mediate Epithelial Cell Responses to Lipopolysaccharides,”FASEB J., A142 (1993).
Geller et al.,Arch. Surg., 128:22-28 (1993).
Tobias,J. Biol. Chem., 263:13479-13481 (1988).
Schumann,Science, 249:1429-1431 (1990).
Dubin et al., “Asthma and Endotoxin: Lipopolysaccharide-Binding Protein and Soluble CD14 in Bronchoalveolar Compartment,”Am. J. Physiol., 270:L736-L744 (1996).
Froon et al., “Lipopolysaccharide Toxicity—Regulating Proteins in Bacteremia,”J. Infect. Dis., 171:1250-1257 (1995).
Heumann et al., “Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma,”J. Immunol. Meth., 171:169-176 (1994).
Iriye et al., “Differences in the Concentration of an Endotoxin Binding Protein Help Explain Sensitivity to Septic Complications in Pregnancy,”Am. J. Obstetrics Gynecol., 174(1 pt. 2):390 (1996).
Nakayama et al., “Monitoring Both Serum Amyloid Protein A and C-Reactive Proteins as Inflammatory Markers in Infectious Diseases,”Clin. Chem. 39:293-297 (1993).
Schumann et al., 36th Int'l Conf. on Antimicrobial Agents and Chemotherapy, New Orleans, LA, Sep. 15-18, (1996).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for quantifying LBP in body fluids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for quantifying LBP in body fluids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for quantifying LBP in body fluids will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3555488

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.